分类： health

China’s National Healthcare Security Administration (NHSA) has launched a comprehensive framework of national pricing guidelines that aims to streamline access to innovative medical treatments and standardize essential care services for elderly and pediatric populations, marking a major step forward in balancing technological innovation, industry development and public affordability.

As of the latest update, the administration has rolled out 39 batches of these guidelines, covering approximately 180 categories of emerging medical technologies, products and care services. The new framework establishes unified national standards for service nomenclature, clinical definitions, and overarching pricing structures across all public healthcare institutions, while leaving authority for local governments to set final, context-specific fee levels aligned with regional economic conditions.

Speaking at a press conference held on Monday, Dong Zhaohui, deputy director of the NHSA’s price bidding and purchasing department, outlined that the guidelines encompass a wide range of groundbreaking novel therapies. These include high-tech interventions such as surgical robotics, remote surgical procedures, brain-computer interface (BCI) implants, artificial heart devices, cochlear implants, artificial larynx devices, and high-intensity focused ultrasound treatment. When China granted the world’s first commercial approval for a BCI implant in March this year, the corresponding pricing guideline was released immediately to support rapid clinical rollout.

Beyond neurological and device-based innovations, the framework also covers cutting-edge cancer treatments, including proton radiotherapy, heavy ion radiotherapy, and boron neutron capture therapy — interventions that have long been out of reach for many patients due to unclear pricing and limited infrastructure. Dong explained that when drafting the guidelines, regulators factored in multiple key priorities: fair returns for medical innovators, cost burdens for healthcare institutions, equitable patient access to new treatments, and practical implementation data from pilot regions such as Shanghai. The guidelines explicitly set reasonable payment caps per full treatment course, with a core goal of expanding affordable access for patients across the country.

To further accelerate the adoption of life-saving new technologies, Dong added that the NHSA is exploring a proactive pre-approval pricing model, which would release guidance during the clinical trial stage of novel therapies, rather than waiting for full commercial approval. This early clarity is expected to cut development timelines and help bring new treatments to patients faster.

Industry analysts and healthcare experts say the standardized pricing framework is already unlocking growth across China’s medical innovation ecosystem. Jiang Changsong, a professor at the National Institute of Healthcare Security at Capital Medical University, noted that under the new guidelines, government-referenced prices for invasive BCI implantation sit at around 7,000 yuan ($873) per procedure in Beijing, Hubei and Zhejiang, while non-invasive BCI implantation is priced at roughly 1,000 yuan.

“With a clear pricing benchmark in place, medical enterprises can accurately calculate the return cycle for their R&D investments, which makes investors far more willing to commit capital to innovation. Hospitals also gain a transparent, official basis for service charging, and as a result, the entire industry chain is put into smooth motion,” Jiang explained. He added that the guidelines have already had a tangible impact on advanced cancer radiotherapy infrastructure: with a clear price anchor in place, more regional governments are confident in planning and constructing new proton therapy centers, which will eventually eliminate the need for patients to travel long distances across the country and wait in lengthy queues for life-saving treatment.

For domestic medical device manufacturers, the standardized pricing framework is leveling the playing field in previously unregulated segments. Xing Yuzhu, executive deputy general manager of Beijing Surgerii Robotics Co, noted that before the new guidelines were introduced, surgical robot services lacked uniform national pricing standards, with fragmented pricing structures largely controlled by a small number of leading international companies. Under the new rules, fee structures for both primary surgical and auxiliary robotic procedures are clearly defined, with tiered pricing set based on the level of robotic involvement in each procedure. This structure enables domestic manufacturers to compete on a more equal footing with global brands while still ensuring they can earn reasonable returns on their innovation investments.

In addition to supporting cutting-edge medical innovation, the new pricing guidelines also address pressing public welfare priorities aligned with China’s policy goals. To support the development of a birth-friendly society, the NHSA has added standardized pricing for a range of childbirth-related services, including fetal color ultrasound examinations, labor pain relief, family companionship during delivery, neonatal inpatient beds, general newborn nursing, and specialized care for premature infants.

To improve access to high-quality, affordable care for China’s aging population, the administration has also introduced standardized pricing items for a full spectrum of elderly care services. These include 24/7 “companion-free” non-medical inpatient care, home care visits, end-of-life hospice care, home-based hospital beds, online follow-up consultations, and remote health monitoring, all designed to bring essential care services closer to elderly populations.

Dong noted that under the guidelines, one-to-several “companion-free” care services are priced between 100 and 180 yuan per day across different regions, far lower than the 300 to 500 yuan typically charged by independent private caregivers. “This framework not only eases the financial burden on families caring for elderly relatives, but also helps attract more skilled talent to the professional nursing industry,” Dong said.

As China prepares for the upcoming five-day May Day holiday starting May 1, the country’s top public health authority has issued a formal warning over growing infectious disease threats, calling for stepped-up public vigilance to curb outbreaks during a period expected to see surges in travel and large-scale public gatherings. In a press briefing held in Beijing on Wednesday, April 22, Xi Jingjing, spokesperson for the National Disease Control and Prevention Administration, announced that influenza and rhinovirus transmission across China has followed a steady upward trajectory since the beginning of April 2026.

With warmer spring temperatures shifting toward summer conditions, the authority is also urging heightened awareness of mosquito-borne and intestinal infectious diseases that typically become more active during this seasonal transition. Xi specifically highlighted four diseases as key priorities for precaution: dengue fever, chikungunya fever, norovirus infection, and hand, foot and mouth disease, all of which carry heightened transmission risk when crowds of travelers converge in shared spaces.

Noting that weather patterns during the shift from spring to summer can be highly unpredictable, with sudden shifts in temperature, Xi offered targeted guidance for the public to reduce their risk of illness. She recommended that travelers pack flexible clothing options to adapt to changing conditions, and that all people planning trips check the latest infectious disease activity updates at their destination before departing. Food and water hygiene, she emphasized, is a critical line of defense against intestinal pathogens spread through contaminated consumption.

For travelers and residents engaging in outdoor activities, Xi urged consistent measures to prevent bites from mosquitoes and ticks, which are increasingly active as temperatures rise. She also advised the public to avoid close contact with wild marmots when hiking or visiting natural areas, a precaution designed to reduce the risk of tick-borne or zoonotic disease transmission.

The National Disease Control and Prevention Administration closed its warning with additional public guidance: all residents, particularly caregivers for children and guardians of older adults, should monitor health closely for any signs of infectious disease in the weeks surrounding the holiday. Anyone who develops symptoms consistent with the highlighted diseases is encouraged to seek prompt medical evaluation to prevent further spread and ensure timely care.

Breast cancer patients globally may soon access a revolutionary new treatment option, developed by a surgical team based in southern China, that eliminates the need for secondary follow-up operations and leaves no visible scarring on the breast — addressing two of the most distressing drawbacks of conventional breast cancer care.

The innovative procedure was created by Liao Ning, lead of the breast surgery department at Guangdong Provincial People’s Hospital, and integrates three cutting-edge medical tools into one streamlined workflow: real-time ultrasound imaging, a fluorescent contrast dye that clearly demarcates tumor tissue from healthy breast cells, and a high-precision robotic surgical system. Peer-reviewed findings from the team’s clinical trials were recently published online in the *European Journal of Surgical Oncology*, marking international recognition of the technique’s safety and efficacy.

In standard breast-conserving surgery, between 10% and 15% of patients require a second procedure to remove residual cancerous tissue that is not detected or excised during the initial operation. Early clinical results for the new Chinese method show a 98.4% rate of complete tumor removal with clear, cancer-free margins, and no patients in the trial cohort required a follow-up surgery to address leftover malignant tissue.

The procedure demands close coordination among the surgical team: after the fluorescent dye is injected directly into the tumor under ultrasound guidance, the team has just five minutes to excise the highlighted tissue before the dye loses its visibility. The robotic system’s high-definition camera translates the invisible tumor boundary into a clear green visualization on the operating screen, while the device’s articulated mechanical arms perform excisions with precision between one and two millimeters — an accuracy that far outperforms manual surgical techniques.

Artificial intelligence also contributes to the procedure’s success before the first incision is made. AI algorithms process pre-operative scans and patient clinical data to construct a detailed 3D model of the tumor, map exact safe cutting margins, and generate a prediction of the breast’s final appearance after resection. This allows surgeons to plan both tumor removal and breast reshaping well in advance, reducing the risk of intra-operative error and suboptimal cosmetic outcomes.

Unlike conventional procedures that require incisions on the breast surface, all tumor removal work for the new method is done through a single small incision hidden in the armpit, leaving the outer breast completely free of visible scarring. For patients who previously faced an agonizing trade-off between cancer survival and preserving their body image and personal dignity, this breakthrough addresses both physical and psychological harms associated with traditional breast cancer treatment.

During a recent international medical exchange visit hosted by Tianjin Hospital, a senior Chinese orthopedic surgeon has drawn widespread praise from a visiting delegation of orthopedic specialists from Malaysia, Jordan, and Armenia after completing a highly complex shoulder procedure in less than an hour.

Cao Jiangang, director of the hospital’s Department of Sports Injuries and Arthroscopy, performed an arthroscopic suture repair to treat a massive rotator cuff tear — a procedure that requires extreme precision and years of specialized training — in just 40 minutes, all while being closely observed by the international visiting team.

The speed of the operation came as a major surprise to many delegates. Qutibeh Abdelqader Ahmed Darwish, a member of the Jordan Sports Medicine Federation and medical supervisor for Jordan’s national sports team, noted that a comparable procedure in his home country would usually take more than three hours to complete. He attributed the remarkable efficiency to two key factors: seamless coordination across the entire surgical team and access to cutting-edge surgical instruments that streamline complex steps of the operation. Darwish added that beyond the impressive speed, the procedure delivered exceptional technical outcomes and aligns fully with the highest leading international standards for orthopedic care, with a documented high long-term success rate for this approach at Tianjin Hospital.

Johan Ahmad, a consultant orthopedic surgeon from Malaysia’s KPJ Damansara Specialist Hospital, also highlighted the institutional strengths that enabled the successful, efficient procedure. He pointed to Tianjin Hospital’s rigorous, detailed preoperative planning process, where multidisciplinary medical teams collaborate closely to combine clinical assessments and advanced imaging to pinpoint the exact location and severity of lesions before entering the operating room. The hospital also maintains clear contingency protocols to address any unexpected complications that may arise during surgery, a practice Ahmad called a model for standardized care. Following the demonstration, Ahmad announced that he plans to send trainee doctors from his facility to Tianjin Hospital to receive hands-on training in these advanced techniques.

Xu Weiguo, Party secretary of Tianjin Hospital, emphasized that the institution has long prioritized open international medical collaboration. He said the hospital welcomes medical professionals from across the globe to exchange knowledge, with the goal of sharing advanced orthopedic techniques, China’s prevention-focused approach to sports rehabilitation, and insights from the country’s public healthcare system with the international medical community.

The demonstration, held in mid-April 2026, marks another milestone in China’s growing engagement with global healthcare networks, showcasing the maturity of specialized surgical care developed in leading Chinese medical centers.

China has marked a new intersection of public health policy and agricultural innovation with the launch of its first domestically developed omega-3 polyunsaturated fatty acid-enriched pork, a breakthrough that addresses long-standing dietary imbalances while reshaping the country’s $200-billion-plus pork industry. The rollout, unveiled Friday, arrives alongside a landmark new national agricultural standard set to take effect May 1, which requires all fortified pork products to maintain omega-3 levels accounting for more than 2% of total fatty acids — creating the first official regulatory framework for this emerging product category.

For decades, public health experts have flagged a critical nutritional shortfall across China’s population: the average daily intake of omega-3 fatty acids sits at just 49 milligrams, less than one-fifth of the globally recommended daily allowance. Compounding this issue is a broader imbalance in the national diet, where Chinese consumers typically consume high volumes of dietary fat, but lack adequate proportions of the heart-healthy polyunsaturated varieties that support long-term wellness.

Omega-3 fatty acids are widely recognized by nutrition researchers for their multifaceted health benefits: they regulate blood lipid levels, reduce cardiovascular disease risk, support healthy inflammatory function, and are critical for fetal and childhood brain development. Experts across agriculture and public health sectors say the new fortified pork product offers a practical, accessible solution to close the country’s omega-3 gap, by integrating nutritional improvement into a food that is already the staple protein source for most Chinese households.

“Developing nutritionally fortified pork products delivers a dual win: it lifts public dietary health outcomes while adding significant value to China’s pig industry,” noted Wang Xiaohong, deputy director of the Institute of Food and Nutrition Development at the Ministry of Agriculture and Rural Affairs. Wang added that the new national standard does more than set a benchmark for omega-3 content: it establishes clear quality requirements across every link of the production and supply chain, laying a foundation for consistent, standardized growth for the niche nutritional pork segment.

Ding Gangqiang, lead nutrition expert at the Chinese Center for Disease Control and Prevention, emphasized that adjusting the fatty acid composition of the national diet through accessible fortified food sources is an urgent public health priority. Unlike less accessible omega-3 sources such as fatty fish or specialized supplements, omega-3-enriched pork fits seamlessly into existing consumer dietary habits, making it easy for everyday households to increase their intake of this essential nutrient, he explained.

The innovation also comes as China’s centuries-old indigenous black pig sector undergoes a major structural transformation. Wang Lixian, chief scientist of the pig genetic breeding innovation team at the Chinese Academy of Agricultural Sciences, explained that the industry has shifted its core focus from simply expanding breed populations and preservation to prioritizing end-product quality and nutritional density. “Nutritional enhancement will become a defining competitive advantage for pork producers moving forward,” he said.

The new product also addresses a pressing challenge facing China’s pork industry today: the market is currently in a prolonged low-price cycle, with live hog and retail pork prices falling to multi-year lows in most regions. Developing high-value, nutritionally differentiated products gives pork producers an alternative pathway for growth, helping them escape the intense price competition that plagues the commodity pork market, Wang added.

The omega-3-enriched pork being launched is developed by Qinglian Food using the indigenous Taihu black pig breed, a variety that has been continuously raised in Jiaxing, Zhejiang Province, for more than 7,000 years. To achieve the natural omega-3 enrichment, producers integrated established breeding techniques for nutritional enhancement and developed custom feed formulas that add natural, omega-3-rich ingredients such as flaxseed. This dietary adjustment allows omega-3 fatty acids to deposit naturally into the pork tissue, rather than relying on artificial fortification after processing.

“Just as human diets require balanced nutrition to support good health, pigs need balanced nutrition to produce healthier food for consumers,” said Miao Yu, head of Qinglian Food’s Taihu black pig brand division. With the new national standard now in place and the first commercial product hitting the market, stakeholders say the launch paves the way for a new wave of value-added agricultural innovation that aligns industry growth with national public health goals.

Against a backdrop of rising life expectancy and growing public focus on proactive health maintenance, a new wave of specialized longevity clinics has emerged across China, meeting surging consumer demand for preventive and personalized anti-aging healthcare services.

One of the earliest success stories of this emerging sector comes from Shanghai’s SinoUnited Health, where Zhu Jie, the clinic’s first registered client, recently completed his three-month personalized program with transformative health outcomes. The 44-year-old entrepreneur, who grappled with chronic stress from his daily work, saw dramatic improvements in weight management and four critical metabolic health markers: blood pressure, blood glucose, blood lipids, and uric acid. Beyond measurable biomarker improvements, Zhu reported a complete restoration of daily energy levels that had declined amid years of high-pressure work. Since enrolling in August, he has adopted sustainable, long-term changes to his diet, sleep routine and exercise habits, shifts that have already produced visible results. “I can finally fit into shirts I haven’t worn in more than 10 years,” Zhu said. “At my recent class reunion, everyone told me I look younger than I did years ago. That positive feedback has motivated me to stick to these healthy habits and build a solid foundation for healthy aging down the line.”

Zhu’s experience is just one example of a rapidly expanding national trend. Over the past three years, roughly 50 medical institutions across China — including more than 10 leading public hospitals — have launched dedicated longevity or anti-aging clinics. The most recent opening came in March 2026, when Beijing Geriatric Hospital launched a new center focused on proactive health management and anti-aging medicine.

Unlike traditional reactive medical care that treats existing illnesses, these new clinics operate on a preventive, multidisciplinary model focused on pre-symptomatic health. Providers use cutting-edge tools including biological aging markers and artificial intelligence models to conduct comprehensive aging assessments, then develop fully customized intervention plans for generally healthy patients. The core goal is early intervention to slow aging-related decline, prevent the onset of chronic diseases, and help people maintain vitality as they age. Clinicians note that most patients seeking these services are already proactive about their long-term health, driving the sector’s organic growth.

Industry expansion has also received formal policy support. In early 2024, the General Office of the State Council released a national framework for developing the silver economy and improving elderly well-being, which marked the first time the central government explicitly supported development of the anti-aging industry. The policy guidance encourages the integration of advanced biotechnologies — including genetic testing and molecular diagnostics — into efforts to delay age-related diseases, and calls for expanded development of early screening products and services for aging-associated health conditions. Industry analysts say this policy endorsement has accelerated the adoption of comprehensive preventive longevity care among public hospital systems, opening a new chapter for evidence-based anti-aging health services in China.

BEIJING – Latest official data from China’s National Cancer Center confirms meaningful public health progress: the country has recorded consistent drops in the incidence and mortality rates of multiple prevalent cancers, while the overall five-year survival rate for people living with cancer has climbed steadily in recent years.

The figures, unveiled Friday during China’s annual national cancer prevention awareness campaign (held this year from April 15 to 21), show esophageal cancer incidence and mortality falling by roughly 4.5% year-over-year on average. Annual average declines of around 2% have also been registered in death rates for both lung cancer and nasopharyngeal cancer, according to the updated data.

“China has achieved steady progress in cancer prevention and control, bringing more confidence and hope to patients and their families,” noted He Jie, director of the National Cancer Center. He added that China’s overall national cancer incidence now aligns with the global average.

These encouraging outcomes follow a multi-pronged, prevention-first strategy China has rolled out over the past several years to strengthen the country’s anti-cancer defenses. Global research confirms that more than 40% of all cancer cases can be avoided through effective primary prevention, which centers on adopting healthier daily habits and limiting exposure to known carcinogens – a focus that has been central to China’s public health strategy.

In 2023, Chinese health authorities released official guidelines for the high-quality development of national cancer prevention and control. The policy document prioritizes raising public cancer awareness and reducing modifiable cancer risk factors, and sets a national target to reach an 80% public awareness rate for core cancer prevention knowledge by 2030.

To advance this target, China’s National Health Commission (NHC) recently released a set of 15 simple, actionable recommendations for a cancer-conscious healthy lifestyle. The guide has earned the nickname “the national cancer prevention manual” among Chinese social media users for its accessible, practical advice.

Beyond public education, China has built out a extensive multi-tiered cancer prevention and monitoring network that expands access to early cancer screening across the country. Today, cancer registry sites cover 98.6% of all counties and districts nationwide. Screening programs for cervical and breast cancer – two of the most common cancers affecting women globally – now reach 98% of Chinese county-level administrative regions, and the early diagnosis rate for major cancers in priority regions has surpassed 55%.

Wider access to early screening directly enables earlier intervention, which creates a clear path to better long-term outcomes for people with malignant tumors, explained Liu Jixian, head of the Department of Thoracic Surgery at Peking University Shenzhen Hospital. He noted that most patients diagnosed with early-stage cancer can achieve clinical cure through modern, diversified, comprehensive treatment protocols.

Innovation in diagnostic and treatment technologies has also been a key driver of progress in China’s fight against cancer. A domestic-developed CAR-T therapy, for example, is set to open new treatment pathways for people living with advanced gastric cancer – a disease with high prevalence in China and limited effective options for patients who do not respond to standard second-line treatments.

According to Zhang Jingdong, deputy director of Liaoning Cancer Hospital and Institute, the therapy marks a major targeted breakthrough for this patient population. This homegrown therapy is just one example of the rapidly growing innovation capacity of China’s pharmaceutical sector: China currently accounts for roughly one-third of all innovative cancer and general drugs in development worldwide, and outbound licensing deals for Chinese innovative drugs exceeded $130 billion in 2025 alone.

The pace of innovative drug development in China continues to accelerate. Data from the National Medical Products Administration shows that 14 new innovative drugs have already received market approval in 2026, the majority of which are indicated for cancer treatment.

Alongside breakthroughs in pharmaceutical development, artificial intelligence is playing an expanding role in catching cancer at its earliest, most treatable stages. DAMO PANDA, an AI diagnostic system developed by Alibaba’s DAMO Academy, has delivered promising results in early detection of pancreatic cancer – one of the deadliest forms of the disease, with very low early diagnosis rates historically. The technology is already deployed in both large urban hospitals and remote, underserved regions of China.

Looking ahead, NHC official Liu Wen pledged continued expanded support for scientific research into key challenges in cancer prevention and control, to speed the development of new life-saving technologies and therapies. Liu added that further integration of digital and smart health technologies will help break down longstanding regional barriers to care, ensuring more standardized and equitable cancer treatment access across all parts of China.